Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Angelo Belotti, MD, Rossella Ribolla, Valeria Cancelli, MD, Nicola Bianchetti, Claudia Crippa, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marco Chiarini, Luigi Grazioli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2018-99-113022

Published: 2018

Journal Articles

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, MD, Chiara Cattaneo, MD, Enrico Morello, MD, Vincenza Orlando, PharmD, Nicola Bianchetti, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Francesca Schieppati, MD, Aldo M. Roccaro, Marco Chiarini, Mario Morone, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3161.

https://doi.org/10.1182/blood.V130.Suppl_1.3161.3161

Published: 2017

Journal Articles

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

Erika Borlenghi, MD, Mirko Farina, MD, Angela Passi, MD, Chiara Pagani, MD, Elisa Cerqui, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marta Petullà, PharmD, Angelo Belotti, MD, Giuseppina Ruggeri, Giuseppe Rossi, MD

Blood (2016) 128 (22): 3993.

https://doi.org/10.1182/blood.V128.22.3993.3993

Published: 2016

Journal Articles

Autologous Stem Cell Transplant (ASCT) Improves the Prognosis of AL Amyloidosis By Inducing a Higher Organ Response Rates and May be Preferred As First Line Treatment Both in AL and in AL Associated with Multiple Myeloma (MM)

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, Vincenza Orlando, PharmD, Mariella D'Adda, MD, Alessandro Re, MD, Enrico Morello, MD, Chiara Cattaneo, MD, Giuseppe Rossi

Blood (2016) 128 (22): 4634.

https://doi.org/10.1182/blood.V128.22.4634.4634

Published: 2016

Journal Articles

Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study

Blood (2016) 128 (22): 3700.

https://doi.org/10.1182/blood.V128.22.3700.3700

Published: 2016

Journal Articles

High Dose Melphalan Followed By Autologous Stem Cell Transplant in AL Amyloidosis: a Single-Center Experience

Mariella D'Adda, MD, Francesca Schieppati, MD, Samantha Ferrari, MD, Claudia Crippa, MD, Annalisa Peli, MD, Alessandro Re, MD, Enrico Morello, MD, Paola Tozzi, PharmD, Vincenza Orlando, PharmD, Giuseppe Rossi, MD

Blood (2014) 124 (21): 5909.

https://doi.org/10.1182/blood.V124.21.5909.5909

Published: 2014

Journal Articles

Lower Leukocytosis with Biosimilar Compared with Originator G-CSF during Autologous Stem Cell Mobilization after Chemotherapy in Lymphoma and Multiple Myeloma Patients. a Pharmacovigilance Study of “Rete Ematologica Lombarda” (FARMA-REL)

Anna Maria Pelizzari, MD, Paola Tozzi, PharmD, Francesca Bocchio, Maurizio Bonfichi, Silvia Artuso, Nicola Fracchiolla, MD, Valentino Conti, Pierino Ferremi, Camillo Almici, MD, Daria Bettoni, Vincenza Orlando, PharmD, Giuseppe Rossi, MD, Giuliana Muti

Blood (2014) 124 (21): 5836.

https://doi.org/10.1182/blood.V124.21.5836.5836

Published: 2014

NARROW

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

Autologous Stem Cell Transplant (ASCT) Improves the Prognosis of AL Amyloidosis By Inducing a Higher Organ Response Rates and May be Preferred As First Line Treatment Both in AL and in AL Associated with Multiple Myeloma (MM)

Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study

High Dose Melphalan Followed By Autologous Stem Cell Transplant in AL Amyloidosis: a Single-Center Experience

Lower Leukocytosis with Biosimilar Compared with Originator G-CSF during Autologous Stem Cell Mobilization after Chemotherapy in Lymphoma and Multiple Myeloma Patients. a Pharmacovigilance Study of “Rete Ematologica Lombarda” (FARMA-REL)

Email alerts

ASH Publications

American Society of Hematology

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

Autologous Stem Cell Transplant (ASCT) Improves the Prognosis of AL Amyloidosis By Inducing a Higher Organ Response Rates and May be Preferred As First Line Treatment Both in AL and in AL Associated with Multiple Myeloma (MM)

Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study

High Dose Melphalan Followed By Autologous Stem Cell Transplant in AL Amyloidosis: a Single-Center Experience

Lower Leukocytosis with Biosimilar Compared with Originator G-CSF during Autologous Stem Cell Mobilization after Chemotherapy in Lymphoma and Multiple Myeloma Patients. a Pharmacovigilance Study of “Rete Ematologica Lombarda” (FARMA-REL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only